Clinical Trial Update: Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the convenience, tolerability, and safety of switching Alzheimer's patients from rivastigmine capsules to a transdermal rivastigmine pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Exelon Patch (rivastigmine transdermal patch)
• Rivastigmine capsules (rivastigmine)

Snippet

Sponsor: Novartis | Conditions: Alzheimer's Disease | Phase 4 | Status: COMPLETED | Results posted: 2011-03-24